Company Encyclopedia
View More
name
XJZY
002332.SZ
Zhejiang Xianju Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid raw materials and preparations in China and internationally. The company offers gynecological, anesthesia, respiratory, dermatology, generic drug, and other products; active pharmaceutical ingredients (API), such as corticosteroids, sex hormone, progesterone, non-hormone series, newchem API, and intermediates products; and CDMO and CMO services. It also engages in medical equipment production; technical sales; and technological development activities. Zhejiang Xianju Pharmaceutical Co.,Ltd.
3.120 T
002332.SZMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking106/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE4.56%C
    • Profit Margin7.63%B
    • Gross Margin63.18%A
  • Growth ScoreD
    • Revenue YoY-12.94%E
    • Net Profit YoY-55.98%D
    • Total Assets YoY5.15%C
    • Net Assets YoY-0.71%D
  • Cash ScoreC
    • Cash Flow Margin1311.47%B
    • OCF YoY-12.94%E
  • Operating ScoreC
    • Turnover0.51C
  • Debt ScoreA
    • Gearing Ratio17.04%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    XJZY: Injectable Vecuronium Bromide is expected to be selected for centralized procurement

    According to the Zhitong Finance APP, XJZY announced that the company participated in the bidding work for the 11th batch of national centralized drug procurement organized by the National Organization for Drug Procurement Office from October 27 to October 28, 2025. The company's product, Vecuronium Bromide for Injection, is expected to be selected in this centralized procurement. The indications for this drug are: primarily as an adjunct to general anesthesia, used for tracheal intubation during general anesthesia and muscle relaxation during surgery

    Zhitong·
    SZ
    002332
    -0.64%
    Zhitong·
    SZ
    002332
    -0.64%

    XJZY: Acetate Dexamethasone Tablets 0.5mg specification passed the consistency evaluation

    XJZY announced that it recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration regarding Dexamethasone Acetate Tablets. The company's Dexamethasone Acetate Tablets have added a new specification of 0.5mg, which has passed the consistency evaluation of quality and efficacy for generic drugs

    Zhitong·
    SZ
    002332
    -0.64%
    Zhitong·
    SZ
    002332
    -0.64%

    XJZY obtained the domestic production drug registration certificate for estradiol tablets

    According to the Zhitong Finance APP, XJZY announced that the company recently received the "Drug Registration Certificate" for estradiol tablets approved and issued by the National Medical Products Administration. The company's estradiol tablets have been approved for registration. The indications for estradiol tablets are for diseases related to estrogen deficiency and can also be used to prevent osteoporosis

    Zhitong·
    SZ
    002332
    -0.64%
    Zhitong·
    SZ
    002332
    -0.64%

    XJZY and related personnel received a warning letter from the Zhejiang Securities Regulatory Bureau

    XJZY recently received a warning letter from the Zhejiang Securities Regulatory Bureau due to issues in the management and use of raised funds, including failure to follow the required review procedures, payment of expenses unrelated to the fundraising projects, and the mixing of raised funds with self-owned funds

    Zhitong·
    SZ
    002332
    -0.64%
    Zhitong·
    SZ
    002332
    -0.64%

    XJZY: The company's dexamethasone acetate tablets have passed the consistency evaluation of generic drugs

    On August 22, XJZY announced that the company recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration regarding Dexamethasone Acetate Tablets. The company's Dexamethasone Acetate Tablets have passed the consistency evaluation of quality and efficacy for generic drugs. Dexamethasone Acetate Tablets are corticosteroids primarily used for allergic and autoimmune inflammatory diseases, such as connective tissue diseases, severe bronchial asthma, dermatitis and other allergic diseases, ulcerative colitis, acute leukemia, malignant lymphoma, etc

    Zhitong·
    SZ
    002332
    -0.64%
    Zhitong·
    SZ
    002332
    -0.64%
    © 2025 Longbridge｜Disclaimer